| 2461 |
MACIETAN |
MACITENTAN 10 MG |
TABLET |
Bottle |
LONG TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN ADULTS |
NULL |
TONGMENG( LAO) PHARMACEUTICAL CO.LTD |
TONGMENG( LAO) PHARMACEUTICAL AND FOOD CO.LTD |
LAO PDR |
CERTIFICATE RELEASED |
10 L 0736/17 |
20-FEB-2025 |
19-FEB-2030 |
View |
| 2462 |
MOLOTINIB |
MOMELOTINIB 100 MG |
FILM COATED TABLET |
Bottle |
FOR THE TREATMENT OF INTERMEDIATE OR HIGH RISK MYELOFIBROSIS, INCLUDING PRIMARY MF OR SECONDARY MF POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA IN ADULT WITH ANEMIA |
NULL |
TONGMENG( LAO) PHARMACEUTICAL CO.LTD |
TONGMENG( LAO) PHARMACEUTICAL AND FOOD CO.LTD |
LAOS |
CERTIFICATE RELEASED |
10 L 1218/24 |
31-OCT-2024 |
30-OCT-2029 |
View |
| 2463 |
MOLOTINIB |
MOMELOTINIB 150 MG |
FILM COATED TABLET |
Bottle |
FOR THE TREATMENT OF INTERMEDIATE OR HIGH RISK MYELOFIBROSIS, INCLUDING PRIMARY MF OR SECONDARY MF POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA IN ADULT WITH ANEMIA |
NULL |
TONGMENG( LAO) PHARMACEUTICAL CO.LTD |
TONGMENG( LAO) PHARMACEUTICAL AND FOOD CO.LTD |
LAOS |
CERTIFICATE RELEASED |
10 L 1219/24 |
31-OCT-2024 |
30-OCT-2029 |
View |
| 2464 |
MOLOTINIB |
MOMELOTINIB 200 MG |
FILM COATED TABLET |
Bottle |
FOR THE TREATMENT OF INTERMEDIATE OR HIGH RISK MYELOFIBROSIS, INCLUDING PRIMARY MF OR SECONDARY MF POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA IN ADULT WITH ANEMIA |
NULL |
TONGMENG( LAO) PHARMACEUTICAL CO.LTD |
TONGMENG( LAO) PHARMACEUTICAL AND FOOD CO.LTD |
LAOS |
CERTIFICATE RELEASED |
10 L 1220/24 |
31-OCT-2024 |
30-OCT-2029 |
View |
| 2465 |
MYTANNE |
MITOTANE 500 MG |
FILM-COATED TABLETS |
BOTTLE |
MYTANNE IS AN ANTITUMORAL MEDICINE THIS MEDICINE IS USED FOR THE TREATMENT OF SYMPTOMS OF ADVANCED NON OPERABLE, METASTATIC OR RECURRENT MALIGNANT TUMOURS OF THE ADRENAL GLANDS. |
NULL |
TONGMENG( LAO) PHARMACEUTICAL CO.LTD |
TONGMENG( LAO) PHARMACEUTICAL AND FOOD CO.LTD |
LAO PDR |
CERTIFICATE RELEASED |
09 L 0707/16 |
20-SEP-2023 |
19-SEP-2026 |
View |
| 2466 |
OBETAN |
OBETICHOLIC ACID 5 MG |
TABLET |
BOTTLE |
TREATMENT OF PRIMARY BILIARY CHOLANGITIS IN ADULTS |
NULL |
TONGMENG( LAO) PHARMACEUTICAL CO.LTD |
TONGMENG( LAO) PHARMACEUTICAL AND FOOD CO.LTD |
LAO PDR |
CERTIFICATE RELEASED |
10 L 0735/17 |
07-AUG-2024 |
06-AUG-2027 |
View |
| 2467 |
ODXIBAT |
ODEVIXIBAT 0.2 MG |
CAPSULE |
BOTTLE |
USED TO TREAT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS IN PATIENTS AGED 6 MONTHS OR OLDER |
NULL |
TONGMENG( LAO) PHARMACEUTICAL CO.LTD |
TONGMENG( LAO) PHARMACEUTICAL AND FOOD CO.LTD |
LAO PDR |
CERTIFICATE RELEASED |
09 L 1190/24 |
24-SEP-2024 |
23-SEP-2027 |
View |
| 2468 |
ODXIBAT |
ODEVIXIBAT 1.2 MG |
CAPSULE |
BOTTLE |
USED TO TREAT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS IN PATIENTS AGED 6 MONTHS OR OLDER |
NULL |
TONGMENG( LAO) PHARMACEUTICAL CO.LTD |
TONGMENG( LAO) PHARMACEUTICAL AND FOOD CO.LTD |
LAO PDR |
CERTIFICATE RELEASED |
09 L 1189/24 |
24-SEP-2024 |
23-SEP-2027 |
View |
| 2469 |
PEMITINI |
PEMIGATINIB 4.5 MG |
TABLET |
BOTTLE |
TO TREAT BILE DUCT CANCER (ALSO KNOWN AS CHOLANGIOCARCINOMA) WHOSE CANCER CELL HAVE AN ABNORMAL FORM OF THE FGFR2 PROTIEND |
NULL |
TONGMENG( LAO) PHARMACEUTICAL CO.LTD |
TONGMENG( LAO) PHARMACEUTICAL AND FOOD CO.LTD |
LAOS |
CERTIFICATE RELEASED |
07 L 1136/24 |
12-JUL-2024 |
11-JUL-2027 |
View |
| 2470 |
PITOBRUNIB |
PIRTOBRUTINIB 100 MG |
FILM-COATED TABLETS |
BOTTLE |
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR |
NULL |
TONGMENG( LAO) PHARMACEUTICAL CO.LTD |
TONGMENG( LAO) PHARMACEUTICAL AND FOOD CO.LTD |
LAOS |
CERTIFICATE RELEASED |
11 L 1251/24 |
04-DEC-2024 |
03-DEC-2029 |
View |
